Clavis Pharma Receives US Orphan Drug Designation for ELACYT(TM)
26-Jun-2008
"We are pleased to receive this orphan drug designation for ELACYT, in addition to the European Commission designation received last year" says Geir Christian Melen, CEO of Clavis Pharma. "Patients with AML need better agents as current treatment options are highly unsatisfactory. This designation is an important milestone in Clavis Pharma's strategy to achieve marketing approval for ELACYT as swiftly as possible."
Organizations
FDA
Clavis Pharma
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.